|
Female, n (%)*
|
60 (80.0%)
|
61 (81.3%)
|
0.836
|
|
Age at diagnosis, years, median (IQR)
|
45.0 (36.0–53.0)
|
45.0 (37.0–53.0)
|
0.678
|
|
Age at start of 1st line, years, median (IQR)*
|
52.0 (45.0–61.0)
|
55.0 (44.0–61.0)
|
0.811
|
|
Disease duration, years, median (IQR)*
|
5.0 (2.4–12.7)
|
5.8 (3.0–13.1)
|
0.937
|
|
RF positive, n (%)*
|
60 (80.0%)
|
54 (72.0%)
|
0.251
|
|
Presence of comorbidities, n (%)*
|
54 (72.0%)
|
55 (73.3%)
|
0.855
|
|
Currently smoking, n (%)*
|
21 (28.0%)
|
21 (28.0%)
|
1.000
|
|
Number of previous csDMARDs, n (%)*
|
|
0
|
2 (2.7%)
|
0 (0.0%)
|
0.230
|
|
1
|
16 (21.3%)
|
15 (20.0%)
|
|
2
|
20 (26.7%)
|
28 (37.3%)
|
|
3
|
17 (22.7%)
|
20 (26.7%)
|
|
4+
|
20 (26.7%)
|
12 (16.0%)
|
|
Glucocorticoids in previous history, n (%)*
|
67 (89.3%)
|
66 (88.0%)
|
0.797
|
|
Concomitant csDMARDs, n (%)*
|
61 (81.3%)
|
63 (84.0%)
|
0.666
|
|
Concomitant GCs, n (%)*
|
56 (74.7%)
|
55 (73.3%)
|
0.852
|
|
DAS28-ESR (0–10), median (IQR)
|
5.0 (4.2–5.9)
|
5.0 (4.1–5.7)
|
0.717
|
|
TJC (28 joints), median (IQR)*
|
8.0 (4.0–12.0)
|
6.0 (3.0–11.0)
|
0.677
|
|
SJC (28 joints), median (IQR)*
|
4.0 (2.0–8.0)
|
4.0 (2.0–7.0)
|
0.973
|
|
ESR (mm/h), median (IQR)*
|
27.0 (15.0–37.0)
|
25.0 (12.0–41.0)
|
0.844
|
|
CRP (mg/l), median (IQR)*
|
15.0 (8.0–22.2)
|
8.4 (3.5–25.7)
|
0.090
|
|
SDAI (0–86), median (IQR)
|
25.5 (15.6–34.9)
|
22.7 (16.1–30.9)
|
0.531
|
|
PTGA (0–100), median (IQR)*
|
60.0 (40.0–71.0)
|
50.0 (40.0–71.0)
|
0.519
|
|
MDGA (0–100), median (IQR)
|
55.0 (35.0–70.0)
|
45.0 (30.0–60.0)
|
0.059
|
|
HAQ-DI (0–3), median (IQR)*
|
1.5 (1.1–1.9)
|
1.5 (1.1–1.9)
|
0.877
|
|
EQ-5D (− 0.59–1), median (IQR)a
|
0.2 (0.1–0.7)
|
0.6 (0.1–0.7)
|
0.290
|
